Novo Nordisk Hires OpenAI to Speed Obesity Drug Pipeline
What Happened
Novo Nordisk announced a partnership with OpenAI to integrate AI across research, clinical trials, manufacturing, and commercial operations. Pilots begin immediately with full integration targeted by year-end. OpenAI will also train Novo's global workforce on AI literacy. CEO Mike Doustdar framed it as "supercharging" scientists rather than replacing them — a careful message to Novo's 60,000 employees.
My Take
Pharma has historically been the laggard in enterprise AI — too regulated, too slow, too many legacy processes. Novo Nordisk flipping to an OpenAI-powered org-wide deployment is the first real signal that the "wait and see" pharma stance is ending. The Wegovy cash cow is funding the transition, a luxury competitors like Pfizer and Merck don't have. Expect a scramble in Q3 as rivals cut similar deals with Anthropic, Google DeepMind, or Isomorphic Labs to avoid falling behind on discovery timelines.
Read Original Source